HMPL 653
Alternative Names: HMPL-653Latest Information Update: 15 Jan 2024
At a glance
- Originator HUTCHMED
- Class Antineoplastics; Small molecules
- Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Giant cell tumour of tendon sheath; Solid tumours
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)
- 31 Dec 2022 HUTCHMED has patents pending for HMPL 653 in China, USA, Europe and Japan
- 19 Jan 2022 Phase-I clinical trials in Giant cell tumour of tendon sheath in China (unspecified route)